Valuation : Control Bionics Limited

Market Cap 33.13M 23.76M 20.43M 19.28M 17.56M 32.83M 2.27B 230M 88.36M 1.15B 89.22M 87.27M 3.66B P/E 2025
-1.3x
P/E 2026 -3.78x
Enterprise Value 31.59M 22.66M 19.48M 18.38M 16.75M 31.31M 2.17B 219M 84.27M 1.1B 85.08M 83.22M 3.49B EV / Sales 2025
1.4x
EV / Sales 2026 6.07x
Free-Float
73.44%
Yield 2025 *
-
Yield 2026 -
1 day+1.67%
1 week-1.61%
Current month+1.67%
1 month-8.96%
3 months-25.61%
6 months+7.02%
1 week 0.06
Extreme 0.058
0.06
1 month 0.06
Extreme 0.056
0.07
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.7
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 2023-01-18
Director of Finance/CFO - 2024-05-12
Chief Tech/Sci/R&D Officer - 2013-12-31
Director TitleAgeSince
Chairman 66 2025-11-18
Director/Board Member - 2023-01-18
Director/Board Member - 2023-03-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.67%-1.61%+74.29%-19.74% 23.37M
+1.21%-1.64%+20.51%-30.94% 16.65B
-1.77%+7.05%-31.49%+58.12% 1.78B
+0.28%-4.36%-28.17%+22.74% 894M
-0.37%-12.74%-59.29%-83.64% 833M
+0.08%-0.08%+60.83%-2.96% 778M
-2.56%-5.08%-37.23%-49.60% 654M
-5.26%-9.30%-44.97%-48.89% 591M
+3.41%-13.90%-42.55%-38.97% 436M
+2.03%-4.98%+66.96%+47.60% 386M
Average -0.11%-5.14%-2.11%-14.63% 2.3B
Weighted average by Cap. +0.64%-4.94%+9.39%-22.74%

Financials

2025 2026
Net sales 6.14M 4.41M 3.79M 3.58M 3.26M 6.09M 421M 42.59M 16.39M 214M 16.55M 16.19M 679M 4.77M 3.42M 2.94M 2.77M 2.53M 4.72M 327M 33.04M 12.71M 166M 12.84M 12.56M 527M
Net income -6.11M -4.38M -3.77M -3.55M -3.24M -6.05M -419M -42.34M -16.29M -212M -16.45M -16.09M -675M -7.27M -5.21M -4.48M -4.23M -3.85M -7.2M -498M -50.35M -19.38M -253M -19.57M -19.14M -803M
Net Debt -237K -170K -146K -138K -126K -235K -16.27M -1.64M -633K -8.25M -639K -625K -26.21M -1.54M -1.1M -947K -894K -814K -1.52M -105M -10.64M -4.1M -53.41M -4.14M -4.05M -170M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
26-09-11 A$0.0610 +1.67% 140,006
26-09-09 A$0.0600 -3.23% 258,175
26-09-08 A$0.0620 +6.90% 214,999
26-09-07 A$0.0580 -1.69% 367,203
26-09-04 A$0.0590 -4.84% 110,001
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!